SCHEMBL16706524

SCHEMBL16706524

CC(C)(C)OC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccn1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 1/20 0.52
▸ PRSS1 P07477 1/20 0.52
▸ CMA1 P23946 15/20 0.50
▸ ACE P12821 1/20 0.49
▸ CTRC Q99895 1/20 0.47
▸ OPRM1 P35372 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23863946 1.00 F2 (0.52) F2PRSS1CMA1ACECTRC
SCHEMBL24448317 1.00 F2 (0.52) F2PRSS1CMA1ACECTRC
SCHEMBL24447150 0.95 F2 (0.56) F2PRSS1CMA1ACECTRC
SCHEMBL16706511 0.95 F2 (0.56) F2PRSS1CMA1ACECTRC
SCHEMBL28394567 0.95 F2 (0.56) F2PRSS1CMA1ACECTRC
SCHEMBL16702932 0.89 OPRM1 (0.50) F2ACEOPRM1
SCHEMBL23863881 0.89 CMA1 (0.48) F2PRSS1CMA1ACECTRC
SCHEMBL28388489 0.89 CMA1 (0.48) F2PRSS1CMA1ACECTRC
SCHEMBL16706532 0.89 CMA1 (0.48) F2PRSS1CMA1ACECTRC
SCHEMBL28392404 0.88 F2 (0.47) F2PRSS1CMA1ACECTRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12516023-B2 NMDA antagonist prodrugs ASTRAZENECA AB (SE) 2026-01-06 — — US disclosed
CN-111187202-B NMDA antagonist prodrugs 阿斯利康(瑞典)有限公司 2025-01-21 — — CN disclosed
EP-4001272-B1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2024-11-13 — — EP disclosed
EP-4001272-A1 NMDA ANTAGONIST PRODRUGS Astrazeneca AB (SE) 2022-05-25 — — EP disclosed
EP-4001272-A1 NMDA ANTAGONIST PRODRUGS Astrazeneca AB (SE) 2022-05-25 — — EP disclosed
EP-3564234-B1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2021-09-29 — — EP disclosed
US-20210040039-A1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2021-02-11 — — US disclosed
US-10815199-B2 NMDA antagonist prodrugs ASTRAZENECA AB (SE) 2020-10-27 — — US disclosed
US-20190152914-A1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2019-05-23 — — US disclosed
EP-3066091-B1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2019-04-03 — — EP disclosed
US-10207994-B2 NMDA antagonist prodrugs ASTRAZENECA AB (SE) 2019-02-19 — — US disclosed
US-20180037550-A1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2018-02-08 — — US disclosed
US-20180037550-A1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2018-02-08 — — US disclosed
US-9822075-B2 NMDA antagonist prodrugs ASTRAZENECA AB (SE) 2017-11-21 — — US disclosed
US-9822075-B2 NMDA antagonist prodrugs ASTRAZENECA AB (SE) 2017-11-21 — — US disclosed
US-20160280647-A1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2016-09-29 — — US disclosed
US-20160280647-A1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2016-09-29 — — US disclosed
WO-2015067923-A1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2015-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210040039-A1 NMDA ANTAGONIST PRODRUGS GRIN1, GRIN2A, GRIN3A F2 2781/4885PRSS1 2050/4885CMA1 4742/4885
US-10815199-B2 NMDA antagonist prodrugs GRIN1, GRIN2A, GRIN3A F2 2781/4885PRSS1 2050/4885CMA1 4742/4885
US-10207994-B2 NMDA antagonist prodrugs GRIN1, GRIN2A, GRIN3A F2 2781/4885PRSS1 2050/4885CMA1 4742/4885
US-20190152914-A1 NMDA ANTAGONIST PRODRUGS GRIN1, GRIN2A, GRIN3A F2 2781/4885PRSS1 2050/4885CMA1 4742/4885
US-20160280647-A1 NMDA ANTAGONIST PRODRUGS GRIN1, GRIN2A, GRIN3A F2 2781/4885PRSS1 2050/4885CMA1 4742/4885
US-20180037550-A1 NMDA ANTAGONIST PRODRUGS GRIN1, GRIN2A, GRIN3A F2 2781/4885PRSS1 2050/4885CMA1 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback